Oncology Part II Flashcards

1
Q

Trastuzumab (Herceptin)

Mechanism

A

Binds to human epidermal growth factor receptor 2 (HER2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Trastuzumab (Herceptin)

Key Safety Concerns

A

Cardiotoxicity (eg, cardiomyopathy)

Monitor LVEF before & after treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Bevacizumab (Avastin)

Mechanism

A

Binds to vascular endothelial growth factor (VEGF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Bevacizumab (Avastin

Key Safety Concerns

A

Impaired wound healing
* Avoid for 28 days before or after surgery

Thromboembolic events

Hemorrhage/fatal bleeding

Gl perforation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Programmed Death Receptor-1 (PD-1) inhibitors

Drugs

A

Pembrolizumab (Keytruda)

Nivolumab (Opdivo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Inhibitor

Drug

A

Ipilumumab (Yervoy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Key Safety Concerns

PD-1 & CTLA-4

A

Immune-mediated toxicities (eg, endocrinopathies, colitis, hepatotoxicity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Identifying Prostate Cancer

A

Abnormal DRE + PSA > 10 ng/mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Gonadotropin-releasing hormone (GnRH) agonists

Common drugs

A

Leuprolide (Lupron Depot)

Goserelin (Zoladex)

Histrelin (Supprelin LA)
Triptorelin (Trelstar)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Gonadotropin-releasing hormone (GnRH) agonists

Safety concerns

A

↓ bone density
* Prevent with calcium & vitamin D

  • Tumor flare
  • Give with antiandrogen
  • Hot flashes
  • Impotence, gynecomastia
  • Bone pain
  • QT prolongation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Gonadotropin-releasing hormone (GnRH) antagonists

Common drugs

A

Degarelix (Firmagon)

Relugolix (Orgovyx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Gonadotropin-releasing hormone (GnRH) antagonists

Safety concerns

A

Hot flashes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Antiandrogens

Common drugs

A

Bicalutamide (Casodex)

Flutamide

Nilutamide (Nilandron)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Antiandrogens

Safety concerns

A

Hot flashes

Gynecomastia

Hepatotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Vinca Alkaloids

Drugs

A

Vincristine

Vinblastine

Vinorelbine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Vinca Alkaloids

Side Effects

A

Peripheral sensory neuropathy (paresthesias)

Autonomic neuropathy (gastroparesis, constipation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Vinca Alkaloids

Peripheral neuropathy

A

Monitor S/Sx (eg, numbness, paresthesia, pain)

Prevention: Limit single vincristine doses to 2 mg

Tx: Neuropathic pain medications (eg, gabapentin, duloxetine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Vinca Alkaloids

Autonomic neuropathy

A

Monitor S/Sx (eg, Bowel movement frequency)

Prevention & Tx: Symptomatic care (eg, diet modifications, laxatives)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Vinca Alkaloids

Administration

A

Only IV

Prepare in a small IV bag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Tretinoin

Safety Concern

A

Differentiation syndrome (fever, dyspnea, pleural effusion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Tretinoin

Management

A

Systemic steroids (eg, dexamethasone)

Interrupt therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Arsenic trioxide

Safety Concern

A

QT prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Arsenic trioxide

Management

A

Maintain K > 4 and Mg > 1.8 mEq/L

Avoid QT-prolonging drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Bleomycin

Safety Concern

A

Pulmonary toxicity (eg, pulmonary fibrosis)

Hypersensitivity reactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
# Bleomycin Management
Limit lifetime cumulative dose to 400 units Test dose and/or premedicate
26
# Bortezomib & Carfilzomib Safety Concern | Proteasome Inhibitors
Herpes reactivation
27
# Bortezomib & Carfilzomib Management | Proteasome Inhibitors
Antiviral agents (eg, acyclovir, valacyclovir)
28
Immunomodulators Meds
Lenalidomide (Revlimid) Pomalidomid (Pomlyst) Thalidomide (Thalomid)
29
# Lenalidomide, Pomalidomid, & Thalidomide Safety Concern | Immunomodulators
Sever birth defects (need 2 negative pregnancy tests) Thrombosis (DVT/PE)
30
# Lenalidomide, Pomalidomid, & Thalidomide Management | Immunomodulators
REMS program 2 form of contraception or abstain from sex PPx anticoagulation
31
# Pegaspargase Safety Concerns | Modified from of L-asparaginase conjugated w/ polyethylene glycol
Hypersensitivity Reactions
32
# Pegaspargase Management | Modified from of L-asparaginase conjugated w/ polyethylene glycol
Premedication w/ APAP, diphenhydramine & an H2RA
33
What does rituximab target?  A. EGFR  B. VEGF  C. CD20  D. HER2  E. PD-1
CD20 | Brand (Rituxan) ## Footnote Rituximab binds to the CD-20 antigen on the B-cells, so patients must be CD20 positive in order to use rituximab. CD refers to the Leukocyte Cluster of Differentiation antigens.
34
On day 5 of the chemotherapeutic regimen, he complains of tingling, numbness and pain in his fingers.  Which of his chemotherapeutic medications is most likely causing these symptoms?  A. Rituximab  B. Cyclophosphamide  C. Doxorubicin  D. Vincristine  E. Prednisone
Vincristine ## Footnote Vincristine is notable for causing peripheral neuropathies.
35
Which agents are cell cycle independent?
Alkylating agents (eg, cyclophosphamide) Anthracyclines (eg, doxorubicin) Platinum compounds (eg, cisplatin)
36
Which agents work on the S phase?
Antimetabolites (eg, methotrexate) Topoisomerase I inhibitors (eg, irinotecan)
37
Which agents works on the G2 phase?
Etoposide Bleomycin
38
Which agents works on the M phase?
Taxanes Vinca alkaloids
39
# Pyrimidine analog antimetabolites MOA
S phase Incoporates into DNA by interfering w/ certain nucleotides in RNA & DNA Flurorouracil inhibits thymidylate synthase
40
# Pyrimidine analog antimetabolites Drugs
Fluoro**uracil** Capecitabine ## Footnote Capecitabine is converted into Fluorouracil
41
# Pyrimidine analog antimetabolites What is given w/ fluorouracil to ↑ efficacy?
Leucovorin or Levoleucovorin
42
# Pyrimidine analog antimetabolites Adverse Effects
Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia) GI Toxicities: Diarrhea, mucositis Severe toxicities ↑ w/ dihydropyrimidine dehydrogenase (DPD) deficiency ## Footnote DPD breaks down Fluorouracil
43
# Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia) Monitoring
S/Sx (eg, painful erythema, skin peeling)
44
# Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia) Management
Limit daily activities to reduce pressure to hands & feet Avoid heat exposure Apply cold compresses for temporary relief Use emollients or topical steroids Modify doses or interrupt therapy for severe cases
45
# Dihydropyrimidine dehydrogenase (DPD) deficiency Prevention
Pharmacogenomic testing
46
# Dihydropyrimidine dehydrogenase (DPD) deficiency Treatment of toxicities
Antidote: uridine triacetate for overdose or early-onset toxicity Symptomatic care (specific to the toxicity)
47
# Pyrimidine analog antimetabolites Drug intxn
Warfarin: Monitor INR (↑) & S/Sx of bleeding
48
# Folate Antimetabolites MOA
S phase Inhibits dihydrofolate reductase → inhibits tetrahydrofolate activation → inhibiting purine & pyrimidines synthesis
49
# Folate Antimetabolites Toxicities
Nephrotoxicity (w/ high doses ≥ 500 mg/m2) GI toxicity (eg, diarrhea, mucositis)
50
# Folate Antimetabolites: Nephrotoxicity Monitoring
Renal function (eg, BUN, SCr) Wt gain Urine pH (target ≥ 7) Methotrexate levels
51
# Folate Antimetabolites: Nephrotoxicity Prevention
Leucovorin or levoleucovorin "rescue" IV sodium bicarbonate hydration to alkalinize the urine Avoid interaction meds (eg, NSAIDs, salicylates)
52
# Folate Antimetabolites: Nephrotoxicity Treatment
Antidote: glucarpidase rapidly lowers MTX levels
52
53
53
# Folate Antimetabolites: GI toxicity Monitoring
S/Sx (eg, BM frequency, painful mouth ulcers)
54
# Folate Antimetabolites: GI toxicity Prevention & Treatment
Diarrhea: antidiarrheals, hydration, electrolyte repletion Mucositis: various Leucovorin or levoleucovorin "rescue"
55
# Folate Antimetabolites: GI toxicity: Mucositis Monitoring
S/Sx (eg, painful mouth ulcers, difficulty eating) S/Sx of infections (eg, thrush)
56
# Folate Antimetabolites: GI toxicity: Mucositis Prevention
Good oral hygiene (eg, brushing with a soft toothbrush) Hold ice chips in the mouth Frequent rinsing with bland rinses (eg, sodium bicarbonate solution)
57
# Folate Antimetabolites: GI toxicity: Mucositis Treatment
Continue good oral hygiene and frequent rinsing Symptomatic care (eg, viscous lidocaine 2%, magic mouthwash) Parenteral nutrition or IV hydration in some cases Thrush treatment (eg, nystatin oral suspension, clotrimazole troches) if indicated
58
# Tyrosine Kinase Inhibitors Bind to BCR-ABL fusion gene
Imatinib (Gleevec) Dasatinib (Sprycel) Nilotinib (Tasigna)
59
# Tyrosine Kinase Inhibitors: Bind to BCR-ABL fusion gene Safety Concerns
Fluid retention QT prolongation (nilotinib [Tasigna] ← greatest risk) * Assess QT interval with an ECG * Correct electrolyte abnormalities * Avoid concurrent QT-prolonging drugs & strong CYP3A4 inhibitors Gl upset (eg, abdominal pain) * Take imatinib with food
60
# Tyrosine Kinase Inhibitors Bind to protein kinase BRAF
Dabrafenib (Tafinlar) Vemurafenib (Zelboraf)
61
# Tyrosine Kinase Inhibitors: Bind to protein kinase BRAF Safety Concerns
New malignancies QT prolongation
62
# Tyrosine Kinase Inhibitors Bind to mitogen-activated extracellular kinase (MEK)
Cobimetinib (Cotellic) Trametinib
63
# Tyrosine Kinase Inhibitors: Bind to MEK Safety Concerns
Retinopathy Rhabdomyolysis
64
# Tyrosine Kinase Inhibitors Bind to epidermal growth factor receptor (EGFR)
Afatinib (Gilotrif) Erlotinib (Tarceva)
65
# Tyrosine Kinase Inhibitors: EGFR Safety Concerns
Dermatologic toxicity (eg, acneiform rash) Use general skin care (eg, sunscreen) & PPx measures (eg, antibiotics)